Lupin Pharmaceuticals Initiates Class II Recall of Clomipramine Hydrochloride Capsules Due to Degradation
Lupin Pharmaceuticals Inc. has voluntarily recalled 2,724 bottles of Clomipramine Hydrochloride Capsules USP 25 mg (Lot # M300464) due to out-of-specification degradation products. This Class II recall, initiated on June 27, 2025, and terminated on January 5, 2026, impacts nationwide distribution. Procurement and regulatory teams must assess immediate supply chain exposure and reinforce quality assurance protocols for generic antidepressants.
Lupin Pharmaceuticals' Class II Recall of Clomipramine Hydrochloride Capsules: Key Findings
Lupin Pharmaceuticals Inc. initiated a voluntary Class II recall for its Clomipramine Hydrochloride Capsules USP 25 mg, specifically targeting Lot # M300464. The recall, identified as D-0537-2025, was prompted by a critical quality failure: an out-of-specification (OOS) result observed for an unspecified degradation product during routine retention sample testing at expiry. This OOS result, detected as the product approached its June 2025 expiration date, indicates a stability issue that could compromise the drug's efficacy and safety profile over time. A total of 2,724 bottles of the 25 mg strength, identified by NDC# 68180-492-01, were distributed nationwide across the United States. The recall was initiated on June 27, 2025, and officially terminated by the FDA on January 5, 2026, signifying that the firm's corrective actions for this specific lot were deemed sufficient. For procurement directors, this event underscores the imperative of stringent quality oversight throughout a product's lifecycle, extending beyond initial release to include stability monitoring. Regulatory affairs heads must ensure their organizations are prepared to manage such recalls efficiently, from identification to final disposition, especially for products with nationwide distribution. Business development executives should note the potential for temporary market disruption and the importance of maintaining robust product quality to preserve brand reputation in competitive generic markets.
Clomipramine Hydrochloride Market Profile and Lupin's Role in Supply
Clomipramine Hydrochloride Capsules, a human prescription drug, is a tricyclic antidepressant primarily used for treating obsessive-compulsive disorder (OCD). Lupin Pharmaceuticals Inc., operating from its Naples, Florida location (5801 Pelican Bay Blvd, Suite 500, Naples, FL 34108-2755), is a significant manufacturer of this generic formulation, holding an Abbreviated New Drug Application (ANDA209294) for the product. The specific recalled product, Clomipramine Hydrochloride Capsules USP 25 mg, is part of a broader offering that includes various strengths, identified by product NDC codes such as 68180-492, 68180-493, and 68180-494. The recall focused on the 25 mg strength, impacting 2,724 bottles from Lot # M300464. For procurement teams, this highlights the need to understand the full product portfolio and market share of key generic suppliers like Lupin. While the recalled quantity is specific, any quality issue with a widely distributed generic molecule can prompt a review of supply chain resilience. Regulatory affairs professionals should monitor the status of ANDA209294 and related products for any broader implications, ensuring their internal quality systems align with FDA expectations for generic drug stability. Business development executives should evaluate the competitive landscape for Clomipramine Hydrochloride, as quality issues can create opportunities for alternative suppliers to gain market share.
Supply Chain Exposure and Mitigation for Downstream Formulators
The nationwide distribution of the affected Clomipramine Hydrochloride Capsules USP 25 mg from Lupin Pharmaceuticals Inc. means that procurement directors across the United States must immediately assess their inventory. Any stock from Lot # M300464, with an expiry date of June 2025, should be identified, quarantined, and returned in accordance with Lupin's recall instructions. The Class II classification, indicating that exposure to the violative product may cause temporary or medically reversible adverse health consequences, necessitates a prompt and thorough response to minimize patient risk and maintain regulatory compliance. For supply chain VPs, this event underscores the critical importance of robust supplier qualification programs that include rigorous stability data review and ongoing quality audits. Relying solely on a single source for critical generic medications can expose organizations to significant disruption. Business development executives should evaluate the potential for customer impact and proactively communicate with clients regarding any supply adjustments. This incident serves as a clear reminder that even voluntary, firm-initiated recalls can have tangible operational and reputational consequences, necessitating diversified sourcing strategies and comprehensive risk management frameworks to safeguard continuous supply and patient safety.
Alternative Sourcing Strategies and Quality Assurance Imperatives
While specific alternative suppliers for Clomipramine Hydrochloride were not detailed in the provided intelligence, this recall by Lupin Pharmaceuticals Inc. serves as a critical prompt for procurement directors to re-evaluate their sourcing strategies for this molecule and other essential generic drugs. Diversifying the supplier base is paramount to building supply chain resilience and mitigating the impact of quality-related disruptions. Organizations should identify and qualify multiple manufacturers for key active pharmaceutical ingredients (APIs) and finished drug products, ensuring geographic diversity to reduce geopolitical and logistical risks. Qualification timelines for new suppliers can be extensive, often spanning 12-24 months, encompassing audits, analytical testing, and regulatory filings. Therefore, proactive identification and qualification of alternative sources, even when current supply appears stable, is a strategic imperative. Regulatory affairs heads must ensure that any new supplier qualifications meet all FDA requirements, including stability data and manufacturing controls. This incident highlights that robust quality agreements, enhanced incoming material testing, and maintaining strategic buffer stock are indispensable components of a resilient supply chain, protecting against unforeseen events like degradation specification failures and ensuring uninterrupted patient access to critical medications.
Broader Regulatory Context and Future Compliance Outlook for Generics
The Class II recall of Clomipramine Hydrochloride Capsules by Lupin Pharmaceuticals Inc., although specific to a single lot and now terminated, reflects the FDA's ongoing vigilance regarding product quality and stability within the generic drug industry. The detection of an out-of-specification degradation product during retention sample testing emphasizes the agency's expectation for manufacturers to maintain product integrity throughout its stated shelf life. This event, while specific to Lupin, occurs within a broader regulatory landscape characterized by heightened scrutiny. Recent parallel events, such as Essential Wellness Pharma's Class II recall of Progesterone Injection due to sterility assurance failures in June 2026, and the FDA hearing concerning Amgen's Tavneos market future, underscore the continuous regulatory pressure across various therapeutic areas and product types. For regulatory affairs heads, this signifies that robust quality management systems, comprehensive stability programs, and proactive communication with regulatory bodies are non-negotiable. Supply chain VPs must recognize that regulatory compliance directly impacts supply continuity and market access. This incident serves as a reminder for all stakeholders that maintaining high-quality manufacturing and rigorous testing protocols is essential to navigate the complex and demanding regulatory environment, ensuring patient safety and sustained market presence.